UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013217
Receipt number R000015423
Scientific Title Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer
Date of disclosure of the study information 2014/02/25
Last modified on 2023/03/01 10:29:41

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer

Acronym

KOBE FOLFIRINOX study

Scientific Title

Feasibility study of FOLFIRINOX as first-line chemotherapy for metastatic pancreatic cancer

Scientific Title:Acronym

KOBE FOLFIRINOX study

Region

Japan


Condition

Condition

pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine Hematology and clinical oncology Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Determining the maximum tolerated dose (MTD) and recommended dose (RD)

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase I


Assessment

Primary outcomes

Proportion of dose limiting toxicity

Key secondary outcomes

safety (adverse event, completion rate), efficacy (overall survival, progression free survival, response rate)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

FOLFIRINOX

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Unresectable metastatic or recurrence pancreatic cancer
2) Histlogically proven adenocarcinoma
3) Age >= 18 years
4) ECOG performance status of 0, 1
5) Previous adjuvant chemotherapy was allowed if relapsed more than 6 months after last administration
6) UGT1A1*6*28 wild type or single hetero
7) No prior chemotherapy and radiotherapy for other malignancies
8) Adequate bone marrow, hepatic, renal, cardiac and respiratory functions
9) Written informed consent

Key exclusion criteria

1) active synchronous or metachronous malignancy other than carcinoma in situ
2) pregnant or nursing
3) severe mental disorders
4) systemic steroid user
5) diabetes mellitus, uncontrolled
6) history of myocardial infarction, unstable angina within 3 months prior to the registration
7) serious coexisting illness
8) active infection
9) peripheral neuropathy greater than Grade 2
10) diarrhea greater than Grade 2
11) ileus
12) massive pleural effusion,ascites
13) history for allergy of L-OHP,CPT-11,5-FU,L-LV,bevacizumab

Target sample size

18


Research contact person

Name of lead principal investigator

1st name Hisateru
Middle name
Last name Yasui

Organization

Kobe City Medical Center General Hospital

Division name

medical oncology

Zip code

650-0047

Address

2-1-1, Minatojima minamimachi,chuo-ku,Kobe city,Hyogo 650-0047 Japan

TEL

0783024321

Email

hyasui@kcho.jp


Public contact

Name of contact person

1st name Hisateru
Middle name
Last name Yasui

Organization

Kobe City Medical Center General Hospital

Division name

medical oncology

Zip code

650-0047

Address

2-1-1, Minatojima minamimachi,chuo-ku,Kobe city,Hyogo 650-0047 Japan

TEL

0783024321

Homepage URL


Email

hyasui@kcho.jp


Sponsor or person

Institute

Kobe City Medical Center General Hospital

Institute

Department

Personal name



Funding Source

Organization

Kobe City Medical Center General Hospital

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe City Medical Center General Hospital

Address

2-1-1, Minatojima minamimachi,chuo-ku,Kobe city,Hyogo 650-0047 Japan

Tel

0783024321

Email

ctc-crc@kcho.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

神戸市立医療センター中央市民病院(兵庫県)


Other administrative information

Date of disclosure of the study information

2014 Year 02 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 02 Month 10 Day

Date of IRB

2014 Year 02 Month 10 Day

Anticipated trial start date

2014 Year 02 Month 25 Day

Last follow-up date

2015 Year 07 Month 31 Day

Date of closure to data entry

2016 Year 07 Month 31 Day

Date trial data considered complete

2016 Year 07 Month 31 Day

Date analysis concluded

2016 Year 07 Month 31 Day


Other

Other related information



Management information

Registered date

2014 Year 02 Month 21 Day

Last modified on

2023 Year 03 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015423


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name